The latest market price of ustekinumab in 2025

As of2025, the selling price of ustekinumab (Ustekinumab) in the Chinese market remains at a high level. As a key biological agent for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis and inflammatory bowel disease, the imported original drug Stelara® usually costs tens of thousands of yuan per injection. Since the drug has not yet been fully included in the national medical insurance, the actual amount paid by patients varies depending on regional and hospital policies, which puts greater financial pressure on some patients.

In recent years, with the successive launch of multiple ustekinumab biosimilars around the world, market competition has intensified, driving prices down gradually. Especially in the U.S. market, the price of biosimilar drugs is about 15% to 20% lower than that of original drugs, significantly improving drug accessibility for patients. This trend also brings hope to the Chinese market. It is expected that after biosimilar drugs are approved for marketing in China in the future, the overall treatment cost of ustekinumab will decrease significantly.

Looking to the future, with the development of domestic biosimilar drugs and the gradual improvement of medical insurance policies, the market price of ustekinumab is expected to become more reasonable. Patients can obtain more affordable treatment options through medical insurance reimbursement, reduced out-of-pocket costs, and the choice of biosimilar drugs. This is particularly important for patients who have long relied on the drug to control their condition, helping to reduce the financial burden of long-term treatment.

In general, 2025 ustekinumab will still be mainly imported original drugs in the Chinese market, with higher prices but definite efficacy. When taking medication, patients should consider their own financial situation, consult professional doctors and pharmacists, and choose a reasonable treatment plan. At the same time, we should pay attention to the launch of biosimilar drugs and medical insurance developments, and actively use relevant policies and assistance projects to improve the continuity and affordability of treatment.

Reference materials:https://www.drugs.com